(HealthDay News) — For patients with heart failure or all-cause index hospitalization, cardiac resynchronization therapy (CRT) devices equipped with the Medtronic AdaptivCRT (aCRT) algorithm correlate with a reduction in 30-day readmission, according to a study published online June 10 in JACC: Heart Failure.

Randall C. Starling, MD, MPH, from the Cleveland Clinic, and colleagues examined the impact of aCRT on 30-day readmissions after heart failure and all-cause index hospitalizations using data from the Adaptive CRT trial. Patients were randomized to aCRT (318 patients) or CRT with echocardiographic-optimization (Echo; 160 patients). Patients were followed for a mean of 20.2 months. The proportion of heart failure and all-cause hospitalizations that had readmission within 30 days was compared.

The researchers found that the 30-day readmission rate was 19.1% in the aCRT group and 35.7% in the Echo group for heart failure (odds ratio, 0.41). The corresponding 30-day readmission rates were 14.8 vs. 24.8%, for all-cause hospitalization (odds ratio, 0.54). Beyond 30 days there was also a significant reduction in the risk of readmission following heart failure or all-case index hospitalization with aCRT.

“aCRT is associated with a significant reduction in the probability of a 30-day readmission following both heart failure and all-cause hospitalizations,” the authors write.

Several authors disclosed financial ties to Medtronic, which funded the study.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)